{
  "protocolSection": {
    "identificationModule": {
      "nctId": "NCT04175704",
      "orgStudyIdInfo": {
        "id": "UBP-A115-IgE"
      },
      "organization": {
        "fullName": "United BioPharma",
        "class": "INDUSTRY"
      },
      "briefTitle": "Evaluating the Safety and Tolerability and Determining the PK and PD of Single Dose UB-221 in Chronic Spontaneous Urticaria",
      "officialTitle": "A Phase I, Randomized, Single-Blind, Placebo-Controlled, Single Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of UB-221 as an Add-on Therapy in Patients With Chronic Spontaneous Urticaria"
    },
    "statusModule": {
      "statusVerifiedDate": "2022-09",
      "overallStatus": "UNKNOWN",
      "lastKnownStatus": "NOT_YET_RECRUITING",
      "startDateStruct": {
        "date": "2023-12-30",
        "type": "ESTIMATED"
      },
      "primaryCompletionDateStruct": {
        "date": "2024-11-30",
        "type": "ESTIMATED"
      },
      "completionDateStruct": {
        "date": "2026-01-30",
        "type": "ESTIMATED"
      },
      "studyFirstSubmitDate": "2019-11-12",
      "studyFirstSubmitQcDate": "2019-11-21",
      "studyFirstPostDateStruct": {
        "date": "2019-11-25",
        "type": "ACTUAL"
      },
      "lastUpdateSubmitDate": "2022-09-29",
      "lastUpdatePostDateStruct": {
        "date": "2022-10-03",
        "type": "ACTUAL"
      }
    },
    "sponsorCollaboratorsModule": {
      "responsibleParty": {
        "type": "SPONSOR"
      },
      "leadSponsor": {
        "name": "United BioPharma",
        "class": "INDUSTRY"
      }
    },
    "oversightModule": {
      "oversightHasDmc": true,
      "isFdaRegulatedDrug": true,
      "isFdaRegulatedDevice": false
    },
    "descriptionModule": {
      "briefSummary": "The study is to evaluate the profiles of safety, tolerability, pharmacokinetics, and pharmacodynamics of UB-221. In this study, safety profile of UB-221 and maximum tolerated dose (MTD) is to be investigated using sentinel dosing strategy. The starting dose of 0.2 mg/kg is selected based on the evaluation and comparison of various approaches including NOAEL, MABEL (minimum anticipated biological effect level), and experiences from other anti-IgE mAb drugs in development.",
      "detailedDescription": "This is a phase I, randomized, single-blind, placebo-controlled, parallel group, single ascending dose study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single dose of UB-221 as an add-on therapy in chronic spontaneous urticaria (CSU) subjects who fail to respond to the first line H1-antihistamine treatment. Only the qualified subjects will be blinded to receive treatment. Each subject will receive only one dose of UB-221 or placebo."
    },
    "conditionsModule": {
      "conditions": [
        "Chronic Idiopathic Urticaria"
      ]
    },
    "designModule": {
      "studyType": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "designInfo": {
        "allocation": "RANDOMIZED",
        "interventionModel": "PARALLEL",
        "primaryPurpose": "TREATMENT",
        "maskingInfo": {
          "masking": "DOUBLE",
          "whoMasked": [
            "PARTICIPANT",
            "OUTCOMES_ASSESSOR"
          ]
        }
      },
      "enrollmentInfo": {
        "count": 32,
        "type": "ESTIMATED"
      }
    },
    "armsInterventionsModule": {
      "armGroups": [
        {
          "label": "Cohort 1",
          "type": "OTHER",
          "description": "0.2 mg/kg UB-221 or placebo",
          "interventionNames": [
            "Drug: UB-221"
          ]
        },
        {
          "label": "Cohort2",
          "type": "OTHER",
          "description": "0.6 mg/kg UB-221 or placebo",
          "interventionNames": [
            "Drug: UB-221"
          ]
        },
        {
          "label": "Cohort 3",
          "type": "OTHER",
          "description": "2 mg/kg UB-221 or placebo",
          "interventionNames": [
            "Drug: UB-221"
          ]
        },
        {
          "label": "Cohort 4",
          "type": "OTHER",
          "description": "6 mg/kg UB-221 or placebo",
          "interventionNames": [
            "Drug: UB-221"
          ]
        }
      ],
      "interventions": [
        {
          "type": "DRUG",
          "name": "UB-221",
          "description": "Name: UB-221 Active ingredient: Anti-IgE monoclonal antibody Dosage form: UB-221 drug product is presented as a sterile liquid for intravenous (IV) infusion. Each vial contains 75 mg/mL UB-221 in 1.12 mL of buffered solution",
          "armGroupLabels": [
            "Cohort 1",
            "Cohort 3",
            "Cohort 4",
            "Cohort2"
          ],
          "otherNames": [
            "recombinant anti-IgE humanized IgG1 monoclonal antibody"
          ]
        }
      ]
    },
    "outcomesModule": {
      "primaryOutcomes": [
        {
          "measure": "To evaluate the safety (Adverse event (AE)/ serious adverse event (SAE)) of UB-221 in CSU patients",
          "description": "1.Adverse event (AE)/ serious adverse event (SAE) reporting: from treatment to EOS",
          "timeFrame": "99 days"
        }
      ]
    },
    "eligibilityModule": {
      "eligibilityCriteria": "Inclusion Criteria:\n\n* Subjects aged â‰¥ 18 years\n* Subjects who are able and willing to provide the informed consent\n* Subjects diagnosed with chronic spontaneous urticaria (CSU) for more than six weeks prior to the screening visit as confirmed by investigators based on medical history.\n\nExclusion Criteria:\n\n* History of significant diseases (other than CSU) or major clinical conditions by the investigator's judgment, such as auto-immune disease or psychiatric and behavioral conditions from which the investigator considers the subject not suitable to participate in this study.",
      "healthyVolunteers": false,
      "sex": "ALL",
      "minimumAge": "18 Years",
      "stdAges": [
        "ADULT",
        "OLDER_ADULT"
      ]
    },
    "contactsLocationsModule": {
      "centralContacts": [
        {
          "name": "Mico Hsu, Master",
          "role": "CONTACT",
          "phone": "+886-3-668-4800",
          "phoneExt": "3201",
          "email": "mico.hsu@unitedbiopharma.com"
        }
      ]
    }
  },
  "derivedSection": {
    "miscInfoModule": {
      "versionHolder": "2026-02-04"
    },
    "conditionBrowseModule": {
      "meshes": [
        {
          "id": "D000080223",
          "term": "Chronic Urticaria"
        }
      ],
      "ancestors": [
        {
          "id": "D014581",
          "term": "Urticaria"
        },
        {
          "id": "D017445",
          "term": "Skin Diseases, Vascular"
        },
        {
          "id": "D012871",
          "term": "Skin Diseases"
        },
        {
          "id": "D017437",
          "term": "Skin and Connective Tissue Diseases"
        },
        {
          "id": "D006969",
          "term": "Hypersensitivity, Immediate"
        },
        {
          "id": "D006967",
          "term": "Hypersensitivity"
        },
        {
          "id": "D007154",
          "term": "Immune System Diseases"
        },
        {
          "id": "D002908",
          "term": "Chronic Disease"
        },
        {
          "id": "D020969",
          "term": "Disease Attributes"
        },
        {
          "id": "D010335",
          "term": "Pathologic Processes"
        },
        {
          "id": "D013568",
          "term": "Pathological Conditions, Signs and Symptoms"
        }
      ]
    }
  },
  "hasResults": false
}